DURECT Corporation (DRRX) News
Filter DRRX News Items
DRRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DRRX News From Around the Web
Below are the latest news stories about DURECT CORP that investors may wish to consider to help them evaluate DRRX as an investment opportunity.
Durect (DRRX) Upgraded to Buy: Here's What You Should KnowDurect (DRRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?Here is how BellRing Brands (BRBR) and Durect (DRRX) have performed compared to their sector so far this year. |
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 MillionDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET® line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm. |
Q3 2024 DURECT Corp Earnings CallQ3 2024 DURECT Corp Earnings Call |
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ...Durect Corp (DRRX) reports increased revenues and reduced expenses, while navigating funding needs for a pivotal Phase 3 trial. |
Durect (DRRX) Reports Q3 Loss, Misses Revenue EstimatesDurect (DRRX) delivered earnings and revenue surprises of 17.65% and 2.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Durect: Q3 Earnings SnapshotCUPERTINO, Calif. AP) — Durect Corp. DRRX) on Wednesday reported a loss of $4.3 million in its third quarter. |
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business UpdateDURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. |
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business UpdateDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Deta |
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024, organized by the American Association for the Study of Liver Diseases (AASLD), to be held November 15-19, 2024 in San Diego, California. |